Vertex Pharma (VRTX) Misses Q4 EPS by 8c, Revenues Beat; Provides FY21 Product Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
February 1, 2021 4:01 PM EST-Full-year 2020 GAAP product revenues of $6.20 billion-
-Full-year 2020 non-GAAP product revenues of $6.20 billion, a 55% increase compared to full-year 2019-
-Company provides full-year 2021 product revenue guidance of $6.7 to $6.9 billion-
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year and fourth quarter ended December 31, 2020 and provided full-year 2021 financial guidance.
"Our achievements in 2020 were marked by a significant increase in the number of people treated with the triple... More
